TCRX — TScan Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1783328 ·
Last close
$0.15
Market Cap
$9.59M
52W High
$1.47
52W Low
$0.14
ADV30
527,049
Next earnings
—
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 586,000 — -33,031,000 -33,085,000 141,401,000 73,038,000 103,390,000
Jun 2026 1,051,000 — -30,493,000 -30,359,000 171,452,000 100,156,000 102,433,000
Mar 2026 982,000 — -29,139,000 -28,666,000 201,991,000 128,057,000 105,069,000
Dec 2025 2,567,000 — -23,858,000 -22,977,000 228,789,000 152,406,000 105,666,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-116,280,000
Investing CF
$46,870,000
Financing CF
$172,000
CapEx
$-2,159,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.94
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-563,887,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-114,923,000
Pretax Income TTM
$-117,712,000
Interest Exp TTM
$2,789,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,111,000
EBITDA
$-115,660,000
Free Cash Flow
$-79,923,872
Enterprise Value
$2,123,914
Total Cash
$100,156,000
Total Debt
$90,893,000
Shares Out
63,502,667
Trailing EPS
$-0.89
Book Value
$2.16
ROE
-95.8%
ROA
-31.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 10,325,000 -135,813,000 -129,766,000 228,789,000 105,666,000 123,123,000 -135,319,000
Dec 2024 2,816,000 -134,821,000 -127,499,000 371,118,000 130,148,000 240,970,000 -110,822,000
Dec 2023 21,049,000 -93,458,000 -89,218,000 272,149,000 121,282,000 150,867,000 -61,358,000
Dec 2022 13,535,000 -66,636,000 -66,221,000 199,091,000 99,657,000 99,434,000 -66,503,000

TTM Snapshot

Revenues TTM
$7,111,000
NetIncome TTM
$-117,712,000
OpCashFlow TTM
—
Assets (Latest)
$171,452,000
Forward EPS
$-0.58

Peers — same industry

TickerNameMarket CapLastDaily %
BCLI BRAINSTORM CELL THERAPEUTICS INC. $9.72M $0.88 —
INAB IN8BIO, INC. $8.86M $0.82 —
INTS INTENSITY THERAPEUTICS, INC. $8.81M $2.67 —
GRML Greenland Mines Ltd $10.87M $3.42 —
BCDA BioCardia, Inc. $11.93M $0.79 —

News headlines (Yahoo Finance, 1h cache)

TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-12 12:00 · Yahoo
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program
2026-09-02 12:30 · Yahoo
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
2026-09-02 11:00 · Yahoo
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
2026-08-12 12:10 · Yahoo
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-12 11:00 · Yahoo
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
2026-07-29 11:00 · Yahoo
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-24 11:00 · Yahoo
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transpl
2026-06-22 11:00 · Yahoo
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-06 11:00 · Yahoo
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
2026-06-02 13:57 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.